Onyx Biotec Limited is a pharmaceutical company specializing in the manufacturing of sterile water for injections, dry powder injections, and dry syrup for both domestic and international markets. Initially established as Onyx Biotec Private Limited in 2005, it transitioned to a public limited company in July 2024. The company's focus lies in providing end-to-end product development and manufacturing solutions, which include preparation and filing of regulatory dossiers for Indian and global clients.
The company operates two manufacturing facilities located in Solan District, Himachal Pradesh. Unit I boasts a production capacity of over 6.3 lakh units of sterile water for injections daily, while Unit II, which commenced commercial production in 2023, has daily capacities of 40,000 units of dry powder injections and 26,667 units of dry syrup in a single shift. These facilities underscore its strengths in pharmaceutical contract manufacturing, serving major pharma corporations globally. Onyx upgraded its annual production capacity from 130 million units to 230 million units during FY 2017-18, reflecting its commitment to scaling operations.
Onyx has a proven track record of capacity expansion and regulatory compliance, making it a competitive player in the pharmaceutical manufacturing space. The company is particularly poised for growth with its diverse service offerings and state-of-the-art infrastructure catering to both the Indian and offshore markets.
To support its growth strategy, Onyx Biotec Limited is planning an IPO of 48,10,000 fresh equity shares, potentially increasing its capital base and enabling further expansion initiatives. For traders, this IPO represents an opportunity to invest in a company with established manufacturing capabilities and a growing market presence in the pharmaceutical sector.
